BluePrint Orphan
Innovation Partner

Rare Disease Business Development – Finding and assessing rare disease pipeline assets for partnering and investment can pose key challenges to companies working to grow their orphan drug presence.

BluePrint Orphan developed RareValue, a search and assessment platform for clinical and preclinical stage investments to help accelerate the orphan asset search process. RareValue offers robust and repeatable analysis across rare and orphan diseases to navigate various risk/reward dynamics and assess the potential of pipeline assets.